Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SMIM2 antisense RNA 1 (SMIM2-AS1) is a long non-coding RNA (lncRNA) gene located on chromosome 13q14.11[3][4]. It does not encode a protein but is thought to participate in gene regulation by interacting with other molecules at the RNA level[1]. The specific biological functions of SMIM2-AS1 remain unclear; however, some research suggests a role in cancer development and progression, although the mechanisms are not fully defined[1][5]. SMIM2-AS1 is not currently considered a therapeutic target, receptor, enzyme, transporter, or similar druggable entity. Key points: - SMIM2-AS1 is a non-protein-coding, long antisense RNA gene[3][4]. - It may be linked to gene regulatory roles and has been mentioned in the context of cancer susceptibility[1][5]. - There are no established drugs, mechanisms of action, or validated biomarkers associated with SMIM2-AS1 at present. - No safety concerns or therapeutic challenges are documented, reflecting its uncertain or indirect disease relevance in current literature.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SMIM2 antisense RNA 1 (SMIM2-AS1).